We asked 3 VCs: would you invest in Elizabeth Holmes’ next startup? | E2353

Jason introduces his framework for credible venture capitalists: those who both actively invest and are willing to discuss their thinking. He contrasts this with people who do the work but won't talk, and those who talk but don't write checks. This establishes the panel's credibility and sets the stage for transparent VC conversation.

Sam and Jason dive into Frederick Hayek's philosophy that markets aggregate dispersed knowledge better than any individual or institution. They apply this to prediction markets and argue for their expansion across domains—skiing conditions, startup valuations, everything. The core idea: never screw with markets because reality is too complicated for centralized thinking.

The panel distinguishes between Nathan Fielder's film as a brilliant work of art and a factual account of Theranos. Fielder uses fictional recreation and unreliable narrators to explore the human condition and the limits of knowability. The film's genius is showing how subjective experience shapes understanding—and why people got duped by Holmes' charisma and vulnerability.

Jason breaks down the key scene where Elizabeth insists her device can run any test while Nathan tries to understand what that means. She plays semantic games—the device can run a test IF the test is built into the platform. But the platform has no tests. She's not lying in her mind; she's exploited ambiguous language. This is the heart of her fraud.

Jason details three investee frauds: an Uber-for-background-checks company, a poop-sampling company that triple-billed insurance, and the fake-JPMorgan-customer female founder. Each went to jail. Jason emphasizes that fraud at 1-2.5% is normal and healthy, signaling sufficient risk-taking. The lesson: due diligence scales with check size, and some fraud is inevitable.

Jason analyzes the scene where Elizabeth scrambles eggs poorly and Billy takes over. She's passively-aggressively performing incompetence to pull people in to help her. Nathan Fielder, Billy Evans, and Amanda Seyfried all get sucked into protecting or fixing her. It's classic sociopathic charisma disguised as vulnerability. This is how she raised hundreds of millions.

Jason tests the panel: Elizabeth calls and pitches a redemption startup. An LP offers to back her and says the product works. Would you take that meeting? Would you invest if there's a 50X flip opportunity? Paige says her gut says no. Sam says he'd take a flip trade but wouldn't hold. Jenny says she's conflicted. The panel concludes that while Adam Neumann can rebuild (he never went to jail), Holmes' prison time and deliberate fraud make her essentially unfundable in venture.

Sam and Jason are emphatic: pro rata rights are contractual promises, not earned privileges. They will never waive them and will fight mega-funds over them. If bullied, call the lead investor and ask them directly why they want to screw you. Jenny and Paige add that younger funds still have to make this case, but it's non-negotiable. The seed business model depends on it.

Using Harmonic.ai data, Jason traces investor participation in three frauds. Theranos had family offices and corporate VCs. FTX had Sequoia, SoftBank, Insight, BlackRock—everyone. They all drafted off each other's diligence and ended up in collective delusion. The lesson: at mega-rounds, investors stop doing their own homework and assume others have vetted. This cascading failure is why diligence matters even more at scale.

Chris Williamson accused Eleven Labs of stealing his voice for their Archer voice clone. Eleven Labs said they hired a different voice actor. The actual voice actor confirmed the hire was legitimate. Now the question is whether Eleven Labs intentionally hired someone to sound like Chris or just found a similar voice. The legal answer is murky (courts haven't decided voice ownership clearly), but the practical answer is: get permission and compensate.

Paige shouts out Knox Metals, a metal servicing platform (like Amazon for metals) that just hit $25M annualized revenue at pre-seed/seed stage. Jenny highlights Electric Plants, which just raised $11M seed for plant intelligence (translating plants' electrical signals into insights for landscaping and carbon accounting). Both showcase practical AI and supply-chain innovation.